Variable | All patients (N = 481) |
---|---|
Age (years) | |
Median (IQR) | 75.0 (69.0–81.0) |
< 65, N (%) | 53 (11.0) |
65–74, N (%) | 168 (34.9) |
≥ 75, N (%) | 260 (54.1) |
Comorbidities, N (%)a | |
No comorbidities reported | 152 (31.6) |
At least one comorbidity reported | 329 (68.4) |
Any Cardiovascular event | 281 (58.4) |
Hypertension | 214 (44.5) |
Angina pectoris | 27 (5.6) |
Myocardial infarction | 24 (5.0) |
Arrhythmia | 45 (9.4) |
Cerebrovascular accident | 12 (2.5) |
Transient ischemic attack | 8 (1.7) |
Other cardiovascular event | 59 (12.3) |
Thromboembolic disease | 10 (2.1) |
Any renal disorders | 52 (10.8) |
Diabetes mellitusb | 71 (14.8) |
ECOG performance status, N (%) | |
Unknown | 202 (42.0) |
0 | 110 (22.9) |
1 | 134 (27.9) |
2 | 31 (6.4) |
3–4 | 4 (0.8) |
Gleason score at initial prostate cancer diagnosis, N (%) | |
Unknown | 46 (9.6) |
≤ 7 | 204 (42.4) |
≥ 8 | 231 (48.0) |
Laboratory parameters, median (IQR) | |
PSA (ng/mL, N = 456) | 56.2 (22.2–133.1) |
Alkaline phosphatase (units/L, N = 357) | 119.0 (81.0–231.0) |
Lactate dehydrogenase (units/L, N = 184) | 277.0 (197.5–382.5) |
Hemoglobin (g/dL, N = 375) | 12.5 (10.8–13.8) |
Location of metastases, N (%) | |
Bone and/or lymph node metastases | 429 (89.2) |
• Bone | 378 (78.3) |
• Non-regional lymph node/s | 63 (13.1) |
• Reginal lymph node/s | 201 (41.8) |
Visceral (non-nodal soft tissue) | 36 (7.5) |
Non-categorised | 16 (3.3) |